HC Wainwright Reaffirms “Buy” Rating for Senseonics (NYSE:SENS)

Senseonics (NYSE:SENS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 184.90% from the company’s previous close.

Separately, StockNews.com began coverage on shares of Senseonics in a research report on Thursday, December 26th. They set a “sell” rating on the stock.

Senseonics Stock Performance

NYSE SENS opened at $0.70 on Wednesday. The stock has a market capitalization of $417.92 million, a PE ratio of -5.40 and a beta of 0.69. Senseonics has a 1-year low of $0.25 and a 1-year high of $1.40. The business has a 50 day simple moving average of $0.86 and a two-hundred day simple moving average of $0.53. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics (NYSE:SENS) last posted its earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same quarter in the previous year, the business earned ($0.07) earnings per share. On average, research analysts predict that Senseonics will post -0.14 EPS for the current fiscal year.

Insider Activity

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Timothy T. Goodnow bought 315,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average price of $0.31 per share, with a total value of $97,650.00. Following the transaction, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in shares of Senseonics during the fourth quarter worth approximately $26,000. HighTower Advisors LLC purchased a new stake in Senseonics in the fourth quarter worth about $32,000. Two Sigma Investments LP bought a new position in Senseonics during the 4th quarter worth about $36,000. Ridgecrest Wealth Partners LLC purchased a new position in Senseonics during the 4th quarter valued at about $60,000. Finally, Northern Trust Corp raised its holdings in shares of Senseonics by 11.2% in the 4th quarter. Northern Trust Corp now owns 1,194,960 shares of the company’s stock valued at $625,000 after purchasing an additional 120,441 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.